Knoedler L, Herfeld K, Schaefer DA, Diatta F, Clune J, Evans B, Seu M, Kim BS, Alfertshofer M, Schaschinger T, Iske J, Knoedler S, Lellouch AG, Jeljeli M, Carturan A, Ruella M, Heiland M, Poeck H, Perl M, Pomahac B, Kauke-Navarro M. CAR-T cell therapy and reconstructive oncologic surgery in peripheral solid tumors-A narrative review. , Cell Rep Med, 6(8): 2025
Shukla D, Manne S, Jiang S, Ruella M, Wherry EJ, Riley JL. Optimal pairing of binder and co-stimulatory domains improves dual CART cell efficacy. , Mol Ther.: 2025
Grzywa TM, Neeser A, Ramasubramanian R, Romanov A, Tannir R, Mehta NK, Cossette B, Morgan DM, Goncalves B, Sukaj I, Bergaggio E, Kadauke S, Myers RM, Paruzzo L, Ghilardi G, Cozzone A, Schuster SJ, Frey N, Zhang L, Yousefpour P, Abraham W, Suh H, Ruella M, Grupp SA, Chiarle R, Wittrup KD, Ma L, Irvine DJ. Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells. , Nat Biomed Eng.: 2025
Guruprasad P, Ramasubramanian R, Nason S, Carturan A, Liu S, Paruzzo L, Hornet V, Plesset J, Patel RP, Bhoj V, Beatty GL, Ruella M. Manufacturing of CRISPR-edited primary mouse CAR T cells for cancer immunotherapy. Manufacturing of CRISPR-edited primary mouse CAR T cells for cancer immunotherapy. , Nat Protoc. : 2025
Lϋӧnd F, Whalen J, Song Y, Schriefer K, Newcombe R, Orlando EJ, Choi SM, Ruella M, Fraietta JA, Schuster SJ, Brogdon JL, Niederst MJ, Treanor LM. DLBCL cells emerge post CD19 CAR-T with cross-antigen resistance and a gene signature predictive of clinical CAR-T response. , Blood Cancer Discov.: 2025
Lϋӧnd F, Whalen J, Song Y, Schriefer K, Newcombe R, Orlando EJ, Choi SM, Ruella M, Fraietta JA, Schuster SJ, Brogdon JL, Niederst MJ, Treanor LM. DLBCL cells emerge post CD19 CAR-T with cross-antigen resistance and a gene signature predictive of clinical CAR-T response. , Blood Cancer Discov.: 2025
Monette A, Aguilar-Mahecha A, Altinmakas E, Angelos MG, Assad N, Batist G, Bommareddy PK, Bonilla DL, Borchers CH, Church SE, Ciliberto G, Cogdill AP, Fattore L, Hacohen N, Haris M, Lacasse V, Lie WR, Mehta A, Ruella M, Sater S, Spatz A, Taouli B, Tarhoni I, Gonzalez-Kozlova E, Tirosh I, Wang X, Gnjatic S. The Society for Immunotherapy of Cancer Perspective on Liquid Biopsy- and Radiomics-Based Technologies for Immuno-oncology Biomarker Discovery and Application. , Clin Cancer Res., 31(12): 2025,2278-2293
Sullivan RJ, Cillo AR, Ferris RL, Jenkins RW, Kluger HM, Kok M, Lipson EJ, Paruzzo L, Redmond WL, Ruella M, Schalper KA, Thommen DS, Tolley K, Yarchoan M, Garnett-Benson C. SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy. , J Immunother Cancer.: 2025
Thomas Luo, Luca Paruzzo, Sandra P. Susanibar Adaniya, Alfred L. Garfall, Matthew Ho, Shivani Kapur, Ruella M, Edward Allen Stadtmauer, Federico Stella, Dan T. Vogl, Adam J. Waxman, and Adam D. Cohen. Disease response at apheresis and association with long-term outcomes following CAR-T cells for relapsed/refractory multiple myeloma (RRMM). , Journal of Clinical Oncology, 43(16): 2025
Stefan K. Barta, Stephen J. Schuster, Jakub Svoboda, Jordan Spencer Carter, Elise A. Chong, Daniel J. Landsburg, Sunita Dwivedy Nasta, Ruchi Patel, Joseph A. Fraietta, Colin Thomas, Aditya Nimmagadda, Lavanya Peddada, Adam Snook, Nicholas Anthony Siciliano, Ruella M, and Rosemary Mazanet. CD5-deleted chimeric antigen receptor cells (Senza5 CART5) to enhance immunotherapy against T-cell non-Hodgkin lymphoma: A first-in-human phase I clinical trial (NCT06420089). , Journal of Clinical Oncology, 43(16): 2025
